REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

5 May 2023 16:30

RNS Number : 6272Y
Arix Bioscience Plc
05 May 2023
 

Arix Bioscience plc( the "Company")

05 May 2023

Total Voting Rights

The Company confirms that its total issued share capital at the close of business on 4 May 2023 comprised 135,609,653 Ordinary Shares of 0.001 pence each fully paid. This figure includes 6,220,145 Ordinary Shares which are held in Treasury, leaving a balance of 129,389,508 Ordinary Shares with each share carrying the right to one vote.

 

The above figure of 129,389,508 may be used by shareholders for the calculations by which they will determine if they are required to notify their major interest in, or a change to their major interest in, Arix Bioscience plc under the Disclosure Guidance and Transparency Rules.

 

 

 

For further information please contact:

Kin Company Secretarial Limited, Company Secretary

+44 20 8819 6486

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRUPURPAUPWGWA
Date   Source Headline
31st Mar 20215:39 pmEQSTransaction in own shares
30th Mar 20215:09 pmEQSTransaction in own shares
30th Mar 20211:02 pmEQSArix leads $152 million Series B financing for Pyxis Oncology
30th Mar 20217:00 amEQSGita Dittmar appointed as Venture Partner
29th Mar 20215:14 pmEQSTransaction in own shares
29th Mar 20217:00 amEQSBoard update
26th Mar 20215:14 pmEQSTransaction in own shares
25th Mar 20214:58 pmEQSTransaction in own shares
24th Mar 20215:05 pmEQSTransaction in own shares
24th Mar 20217:00 amEQSStrategy Implementation Review
23rd Mar 20215:27 pmEQSTransaction in own shares
22nd Mar 20215:57 pmEQSTransaction in own shares
22nd Mar 202111:09 amEQSAura Biosciences announces oversubscribed $80 million financing
22nd Mar 20217:00 amEQSShare buyback programme of up to £25 million
19th Mar 20214:00 pmEQSHolding(s) in Company
15th Mar 20217:30 amEQSHardman & Co Research: Arix Bioscience (ARIX): 32% IRR since inception in 2016
15th Mar 20217:00 amEQSShare buyback programme of up to £25 million
10th Mar 20217:01 amEQSResponse to Activist Shareholder Acacia
9th Mar 20217:01 amEQSArix founds new portfolio company Twelve Bio
9th Mar 20217:01 amEQSAnnual Results for the Twelve Months ended 31 December 2020
25th Feb 20217:00 amEQSBoard Changes
15th Feb 20219:00 amEQSHolding(s) in Company
11th Feb 20217:00 amEQSNotice of Results
10th Feb 20219:00 amEQSAutolus announces pricing of public offering
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension
5th Feb 20219:06 amRNSSecond Price Monitoring Extn
5th Feb 20219:00 amRNSPrice Monitoring Extension
18th Jan 20217:00 amEQSInvestment team changes
12th Jan 20217:00 amEQSHarpoon announces closing of public offering
6th Jan 20212:00 pmEQSImara reports Phase 2a clinical trial results of IMR-687 in adult patients with sickle cell disease  
6th Jan 202110:00 amEQSAutolus provides business outlook for 2021 and 2022
31st Dec 20209:00 amRNSPrice Monitoring Extension
21st Dec 20207:00 amEQSDirector Share Purchase
18th Dec 20208:00 amEQSCompletion of sale of VelosBio
11th Dec 20207:00 amEQSAtox Bio announces FDA acceptance of New Drug Application
8th Dec 20203:45 pmEQSHarpoon reports clinical progress across all pipeline development programmes
7th Dec 20205:48 pmEQSAutolus presents additional data on AUTO3 at ASH
7th Dec 20207:15 amEQSHardman & Co Research: Arix Bioscience (ARIX): Artios attracts Merck KGaA in deal up to $7bn
7th Dec 20207:01 amEQSAutolus presents positive AUTO1 data at ASH
4th Dec 20207:01 amEQSHolding(s) in Company
4th Dec 20207:00 amEQSHolding(s) in Company
3rd Dec 20209:05 amRNSSecond Price Monitoring Extn
3rd Dec 20209:00 amRNSPrice Monitoring Extension
3rd Dec 20208:01 amEQSArtios and Merck KGaA announce global strategic collaboration
12th Nov 20207:00 amEQSArix to Present at the Jefferies Virtual London Healthcare Conference
6th Nov 202012:10 pmEQSHardman & Co Research: Arix Bioscience (ARIX): Hitting the jackpot
5th Nov 20202:06 pmRNSSecond Price Monitoring Extn
5th Nov 20202:00 pmRNSPrice Monitoring Extension
5th Nov 202011:38 amEQSArix Bioscience PLC: VelosBio to be acquired by Merck for $2.75 billion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.